We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

94 hedge funds and large institutions have $48.5M invested in Lineage Cell Therapeutics in 2020 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 23

3% less funds holding

Funds holding: 97 → 94 (-3)

5.45% less ownership

Funds ownership: 42.63% → 37.18% (-5.4%)

8% less capital invested

Capital invested by funds: $52.9M → $48.5M (-$4.41M)

15% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 20

Holders
94
Holders Change
-3
Holders Change %
-3.09%
% of All Funds
1.93%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
21
Increased
17
Reduced
20
Closed
23
Calls
$96K
Puts
–
Net Calls
+$96K
Net Calls Change
-$42K

Top Buyers

1
Jane Street
Jane Street
New York
+$710K
2
Russell Investments Group
Russell Investments Group
United Kingdom
+$670K
3
OMC
Old Mission Capital
Illinois
+$287K
4
PP
Paloma Partners
Connecticut
+$222K
5
DC
Defender Capital
North Carolina
+$202K

Top Sellers

1
BlackRock
BlackRock
New York
-$5.05M
2
State Street
State Street
Massachusetts
-$1.49M
3
Northern Trust
Northern Trust
Illinois
-$915K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$577K
5
N
Nuveen
North Carolina
-$350K
Name Holding Trade Value Shares
Change 		Change in
Stake
SW
51
SkyOak Wealth
Michigan
$13K – – –
GCP
52
GSA Capital Partners
United Kingdom
$13K +$13.4K +15,191 New
QP
53
Quilter Plc
United Kingdom
$12K – – –
ECM
54
ExodusPoint Capital Management
New York
$12K +$11.6K +13,224 New
Millennium Management
55
Millennium Management
New York
$12K +$12.5K +14,200 New
LCM
56
Laurion Capital Management
New York
$11K +$11K +12,476 New
ARTA
57
A.R.T. Advisors
New York
$11K +$11.3K +12,825 New
Simplex Trading
58
Simplex Trading
Illinois
$11K +$11.7K +13,314 New
RJA
59
Raymond James & Associates
Florida
$10K – – –
RAM
60
Riggs Asset Management
Pennsylvania
$10K – – –
Royal Bank of Canada
61
Royal Bank of Canada
Ontario, Canada
$10K +$7.27K +8,262 +269%
Group One Trading
62
Group One Trading
Illinois
$9K – – –
KMWM
63
Keudell/Morrison Wealth Management
Oregon
$9K – – –
Lido Advisors
64
Lido Advisors
California
$9K – – –
OCAM
65
Onex Canada Asset Management
Ontario, Canada
$9K – – –
QPWM
66
Quadrant Private Wealth Management
Pennsylvania
$9K – – –
Cerity Partners
67
Cerity Partners
New York
$9K +$8.8K +10,000 New
JP Morgan Chase
68
JP Morgan Chase
New York
$5K -$153K -173,310 -97%
Citigroup
69
Citigroup
New York
$5K -$27.5K -31,219 -84%
RE
70
RBC Europe
United Kingdom
$4.96K – – –
Bank of Montreal
71
Bank of Montreal
Ontario, Canada
$3K – – –
EWM
72
Edge Wealth Management
New York
$3K – – –
PP
73
Pacifica Partners
Canada
$2K – – –
RFA
74
Reilly Financial Advisors
California
$2K – – –
Osaic Holdings
75
Osaic Holdings
Arizona
$2K +$118 +134 +5%
1 2
3
4 5

LCTX Hedge Fund Activity: Q2 2020 in Review

94 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2020, worth a combined $48.5M — down 8.3% from $52.9M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of LCTX and 21 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 17 added.

The largest buyer was Jane Street, adding an estimated $710K. The largest seller was BlackRock, cutting an estimated $5.05M.

  • 94 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2020, down from 97 in Q1 2020.
  • Funds reported $48.5M of Lineage Cell Therapeutics stock for Q2 2020, down 8.3% quarter-over-quarter.
  • 21 funds opened new Lineage Cell Therapeutics positions in Q2 2020 and 23 closed out, a net change of -2 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2020 was Jane Street, an estimated $710K added.
  • The largest Lineage Cell Therapeutics seller in Q2 2020 was BlackRock, an estimated $5.05M sold.

Based on aggregated 13F filings for Q2 2020.